BioCentury
ARTICLE | Clinical News

MyoKardia to raise funds after reporting HCM data

August 7, 2017 8:59 PM UTC

MyoKardia Inc. (NASDAQ:MYOK) proposed to sell 3.5 million shares in a follow-on after market close on Monday after reporting earlier in the day that lead candidate mavacamten (formerly MYK-461) met the primary endpoint in the first cohort of the Phase II PIONEER-HCM trial to treat symptomatic, obstructive hypertrophic cardiomyopathy. The data, which were reported during market hours, drove the stock up $14.30 (83%) to $31.45. The company ended the day with a market cap just shy of $1 billion.

By year end, MyoKardia plans to start the pivotal EXPLORER-HCM trial of mavacamten...

BCIQ Company Profiles

MyoKardia Inc.

Sanofi

BCIQ Target Profiles

Cardiac myosin